Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA 529.90
+31.40 (6.30%)
Jul 14, 2026, 5:24 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
258.23K ILS
Profits / Employee
-6.27M ILS
Market Cap
21.36M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Bonus BioGroup | 42 |
| BioLineRx | 24 |
| Matricelf | 15 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Geffen Residence & Renewal | 6 |
| BioLight Life Sciences | 4 |
Can-Fite BioPharma News
- 11 hours ago - Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson - TheFly
- 11 hours ago - Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - GlobeNewsWire
- 8 days ago - Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study - GuruFocus
- 8 days ago - Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial - TheFly
- 8 days ago - Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 - GlobeNewsWire
- 12 days ago - CANF Reiterated by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus
- 12 days ago - Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright - TheFly
- 13 days ago - Can-Fite BioPharma (CANF) Reports Positive Results in Namodenoson Study - GuruFocus